Global Market Report - May 18, 2018

Asian markets were higher on renewed optimism about US-China trade talks but the FTSE 100 eased off its record highs

James Gard 18 May, 2018 | 11:05AM
Facebook Twitter LinkedIn

Asia

Markets in the region were modestly higher as investors were today more optimistic about the trade talks between the US and China. This move was in spite of a softer close on Wall Street overnight.

Every day sees a new take on the progress of these negotiations – and in parallel, those between the United State and North Korea – so investors are understandably cautious. Chinese investors were the most optimistic the region, pushing the Shanghai Composite Index up over 1% but after a choppy week the index has not made much progress over the five days.

A four-month low for the yen against the dollar gave its usual support to Japan’s indices.

Europe

FTSE 100 pharmaceutical giant AstraZeneca (AZN) was one of the biggest fallers in the main index on Friday after first-quarter results revealed a fall in profits. Key cholesterol drug Crestor suffered stiff competition from generic drugs. Product sales were boosted by weaker sterling and the company said that generic competition would ease in the latter part of 2018.

The FTSE 100 closed at a record high last night but has so far today failed to make progress on Friday morning as oil stocks struggled after a strong week which saw the crude price hit $80 a barrel.

Eurozone indices were weaker despite gains in Asia.

North America

US economic releases are limited today and the Baker Hughes rig count is the highlight.

Stock futures are indicating a modest rise for US markets on Friday.

Canada inflation for April is also in view with the release of Consumer Price Index, which is expected to remain at 2.3% for the month.

Federal Reserve minutes are due next week for the most recent meeting.

 

 

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
AstraZeneca PLC11,356.00 GBX0.78Rating

About Author

James Gard

James Gard  is senior editor for Morningstar.co.uk

 

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures